missouri medicaid glp 1 covers GLP-1 meds for obesity in just 13 states, analysis finds The GLP-1 Access Gap: Mapping

One notable finding from meta-analyses: cagrilintide demonstrated the lowest odds ratios for nausea, vomiting, and diarrhea when compared to other incretin-based therapies including semaglutide and tirzepatide

H., Wallace, D

However, its use has been associated with various health risks, fueling the current wave of litigation

: 1-2 3

However, this effect was attenuated in the fully adjusted model to entirely resemble the matched analyses (HR 0.87 [0.741.02])

The investigators reported that among the 87,229 subjects in each cohort, treatment with GLP- 1 RAs was associated with a significantly lower risk of overall dementia (10%), Alzheimers disease (12%) and non- vascular dementias (25%)